Literature DB >> 18774970

Inhibitory effects of macrolide antibiotics on exacerbations and hospitalization in chronic obstructive pulmonary disease in Japan: a retrospective multicenter analysis.

Mutsuo Yamaya, Arata Azuma, Hiroshi Tanaka, Hajime Takizawa, Kingo Chida, Yoshio Taguchi, Keiichi Mikasa, Junichi Kadota, Shoji Kudoh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18774970     DOI： 10.1111/j.1532-5415.2008.01725.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN： 0002-8614            Impact factor:   5.562


× No keyword cloud information.
  9 in total

1.  Consider adding this drug to fight COPD that's severe.

Authors:  Keia Hobbs; Dionna Brown
Journal:  J Fam Pract       Date:  2012-07       Impact factor: 0.493

2.  Azithromycin for prevention of exacerbations of COPD.

Authors:  Richard K Albert; John Connett; William C Bailey; Richard Casaburi; J Allen D Cooper; Gerard J Criner; Jeffrey L Curtis; Mark T Dransfield; Meilan K Han; Stephen C Lazarus; Barry Make; Nathaniel Marchetti; Fernando J Martinez; Nancy E Madinger; Charlene McEvoy; Dennis E Niewoehner; Janos Porsasz; Connie S Price; John Reilly; Paul D Scanlon; Frank C Sciurba; Steven M Scharf; George R Washko; Prescott G Woodruff; Nicholas R Anthonisen
Journal:  N Engl J Med       Date:  2011-08-25       Impact factor: 91.245

Review 3.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.

Authors:  Keiichi Mikasa; Nobuki Aoki; Yosuke Aoki; Shuichi Abe; Satoshi Iwata; Kazunobu Ouchi; Kei Kasahara; Junichi Kadota; Naoki Kishida; Osamu Kobayashi; Hiroshi Sakata; Masahumi Seki; Hiroki Tsukada; Yutaka Tokue; Fukumi Nakamura-Uchiyama; Futoshi Higa; Koichi Maeda; Katsunori Yanagihara; Koichiro Yoshida
Journal:  J Infect Chemother       Date:  2016-06-15       Impact factor: 2.211

5.  The non-antibiotic macrolide EM900 inhibits rhinovirus infection and cytokine production in human airway epithelial cells.

Authors:  Nadine Lusamba Kalonji; Kazuhiro Nomura; Tetsuaki Kawase; Chiharu Ota; Hiroshi Kubo; Takeya Sato; Teruyuki Yanagisawa; Toshiaki Sunazuka; Satoshi Ōmura; Mutsuo Yamaya
Journal:  Physiol Rep       Date:  2015-10

6.  Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts.

Authors:  Kosaku Komiya; Shoichiro Ohta; Kazuhiko Arima; Masahiro Ogawa; Shoichi Suzuki; Yasutaka Mitamura; Satoshi Nunomura; Yasuhiro Nanri; Tomohito Yoshihara; Atsushi Kawaguchi; Jun-Ichi Kadota; Bruce K Rubin; Kenji Izuhara
Journal:  Respir Res       Date:  2017-02-20

Review 7.  Bacteria in COPD; their potential role and treatment.

Authors:  Paul T King; Martin MacDonald; Philip G Bardin
Journal:  Transl Respir Med       Date:  2013-08-30

8.  Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy.

Authors:  Atsuya Takeda; Yuichiro Tsurugai; Naoko Sanuki; Tatsuji Enomoto; Masaharu Shinkai; Tomikazu Mizuno; Yousuke Aoki; Yohei Oku; Takeshi Akiba; Yu Hara; Etsuo Kunieda
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

9.  Virus infection-induced bronchial asthma exacerbation.

Authors:  Mutsuo Yamaya
Journal:  Pulm Med       Date:  2012-08-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.